Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements


Disclosures: This work was supported in part by National Institutes of Health (NIH) Grant No. P50 CA97274 to the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence, National Cancer Institute (NCI) Grant No. R01 CA200703, NCI Grant No. U01 CA195568, and the Henry J. Predolin Foundation, Inc. Conflict of interest disclosure: G.S.N. receives research support from Celgene, Roche, MorphoSys, and Bayer and serves on advisory boards for Celgene, Bayer, MorphoSys, and AbbVie. The other authors declare no competing financial interests